Current Report Filing (8-k)
15 September 2018 - 6:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
F
ORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported):
September 11, 2018
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
|
333-
191083
|
|
39-2080103
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
420 Lexington Avenue, Suite 2525, New York, NY
|
|
10170
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: 646-396-4087
(Former name or former address, if changed since last report)
Copies to:
Jeffrey Fessler, Esq.
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 653-8700
Facsimile: (212) 653-8701
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On September 11 and 12, 2018, Dr. Riccardo Dalla-Favera and James Mervis, respectively, resigned as directors of Rasna Therapeutics, Inc. (the “Company”) for personal reasons.
Each of Dr. Dalla-Favera’s and Mr. Mervis’s resignation is not a result of any disagreement with the Company, the Company’s management or the Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: September 14, 2018
|
|
RASNA THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/
Kunwar Shailubhai
|
|
|
|
|
Name: Kunwar Shailubhai
|
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Jan 2025 to Feb 2025
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Feb 2024 to Feb 2025
